Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Cancer Research - Tập 74 Số 11 - Trang 2913-2921 - 2014
Lola Rahib1, Benjamin D. Smith2, Rhonda Aizenberg1, Allison Rosenzweig1, Julie Fleshman1, Lynn M. Matrisian1
1Authors' Affiliations: 1Pancreatic Cancer Action Network, Manhattan Beach, California
22The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Tóm tắt

Abstract Cancer incidence and deaths in the United States were projected for the most common cancer types for the years 2020 and 2030 based on changing demographics and the average annual percentage changes in incidence and death rates. Breast, prostate, and lung cancers will remain the top cancer diagnoses throughout this time, but thyroid cancer will replace colorectal cancer as the fourth leading cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most common cancers, respectively. Lung cancer is projected to remain the top cancer killer throughout this time period. However, pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030, respectively. Advances in screening, prevention, and treatment can change cancer incidence and/or death rates, but it will require a concerted effort by the research and healthcare communities now to effect a substantial change for the future. Cancer Res; 74(11); 2913–21. ©2014 AACR.

Từ khóa


Tài liệu tham khảo

Siegel, 2014, Cancer Statistics, 2014, CA Cancer J Clin, 64, 9, 10.3322/caac.21208

National Cancer Institute Funded Research Portfolio (NFRP)

Smith, 2009, Future of cancer incidence in the United States: burdens upon an aging, changing nation, J Clin Oncol, 27, 2758, 10.1200/JCO.2008.20.8983

Jemal, 2013, Annual Report to the Nation on the Status of Cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels, J Natl Cancer Inst, 105, 175, 10.1093/jnci/djs491

Edwards, 2013 16, Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer, Cancer

Surveillance, Epidemiology, and End Results (SEER)

Matrisian, 2012, The alarming rise of pancreatic cancer deaths in the United States: why we need to stem the tide today, Pancreatic Cancer Action Network

Zauber, 2008, Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force, Ann Intern Med, 149, 659, 10.7326/0003-4819-149-9-200811040-00244

Mandel, 2000, The effect of fecal occult-blood screening on the incidence of colorectal cancer, N Engl J Med, 343, 1603, 10.1056/NEJM200011303432203

Edwards, 2010, Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates, Cancer, 116, 544, 10.1002/cncr.24760

Davies, 2014 20, Current thyroid cancer trends in the United States, JAMA Otolaryngol Head Neck Surg, 10.1001/jamaoto.2014.1

Heller, 2007, Do all cancers need to be treated? the role of thyroglobulin in the management of thyroid cancer: The 2006 hayes martin lecture, Arch Otolaryngol Head Neck Surg, 133, 639, 10.1001/archotol.133.7.639

Welch, 2010, Overdiagnosis in Cancer, J Natl Cancer Inst, 102, 605, 10.1093/jnci/djq099

Bosch, 2004, Primary liver cancer: worldwide incidence and trends, Gastroenterology, 127, S5, 10.1053/j.gastro.2004.09.011

Bruix, 2011, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199

Spanknebel, 2001, Advances in the surgical management of pancreatic cancer, Cancer J, 7, 312

Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369

Ma, 2013, Pancreatic cancer death rates by race among US men and women, 1970–2009, J Natl Cancer Inst, 105, 1694, 10.1093/jnci/djt292

Srivastava, 2008, Translational Research Working Group developmental pathway for biospecimen-based assessment modalities, Clin Cancer Res, 14, 5672, 10.1158/1078-0432.CCR-08-1267

Kaitin, 2010, Deconstructing the drug development process: the new face of innovation, Clin Pharmacol Ther, 87, 356, 10.1038/clpt.2009.293

Scientific framework for recalcitrant cancers 2013, One Hundred Twelfth Congress of the United States of America; 2012 Jan 3

Pancreatic Cancer Action Network

Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC), 2014

Thông tin
Thông tin xuất bản

Cancer Research

Tập 74 Số 11

2913-2921

Thông tin tác giả